OTHER GROUP COMPANIES
market

Natco Pharma’s revenue up by 53% yoy at Rs590.70 crore for Q3FY22

PAT after considering minority interest was Rs80.40 crore for Q3.

February 18, 2022 12:54 IST | India Infoline News Service
Natco Pharma Ltd. reported consolidated total revenue of Rs590.70 crore for Q3FY22 against Rs386 crore for the previous corresponding quarter, up by 53.03% yoy.

The company reported an EBITDA of Rs132 crore for the quarter ended December 2021, as compared to Rs113.30 crore for the previous corresponding quarter, registering a growth of 16.50% yoy.

PAT after considering minority interest was Rs80.40 crore for the current quarter against Rs62.70 crore for the previous corresponding quarter, up by 28.23% yoy.

EBITDA margin for the quarter narrowed to 22.3% for the quarter ended December 2021, against 29.40% for the previous corresponding quarter. PAT margin was 13.6% for Q3FY22 against 16.2% for Q3FY21.

Natco’s total revenue consists of API Revenue at Rs61.70 crore, Formulation revenue at Rs483.40 crore, and revenue from crop health sciences was Rs0.30 crore, and other operating & non-operating incomes stood at Rs45.30 crore.

At around 12.52 PM, Natco Pharma was trading marginally higher at Rs884.20 against its previous closing price of Rs882.50. It touched day’s high of Rs885.75 and low of Rs876 so far.

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity